Skip to main content

Table 3 Predictors of overall survival in patients with brain metastases from breast cancer (univariate analyses)

From: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Covariate Comparison Hazard Ratio
[CI 95%]
P
N = 130
Age at BM diagnosis ≥ 50 Vs. < 50 1.21 [0.80; 1.81] 0.329
KPS ≥ 70 vs. < 70 0.51 [0.34; 0.77] 0.0013
RTOG RPA class III vs. I-II 1.98 [1.32; 2.98] 0.0013
Time interval (y) between primary tumor and BM diagnosis ≥ 2 vs. < 2 3.76 [0.52; 27.18] 0.968
Brain metastases Presence of systemic metastases vs. Alone 1.52 [0.62; 3.74] 0.366
Visceral metastases Yes vs No 1.34 [0.84; 2.11] 0.2159
Bone metastases Yes vs No 1.07 [0.71; 1.60] 0.745
No. of BM Multiple vs. single 1.12 [0.41; 3.06] 0.822
Nb of other metastatic sites Multiple vs. single 1.516 [0.6148; 3.74] 0.3627
Histology lobular and other vs. ductal 0.77 [0.34; 1.77] 0.545
Tumor HR status Negative vs. positive 1.37 [0.91; 2.06] 0.127
HER-2 overexpression Negative vs. positive 1.48 [0.98; 2.24] 0.0606
Trastuzumab-based therapy for HER2 overexpressing tumor Yes vs No 0.45 [0.27; 0.75] 0.001631
HR- & HER2- Yes vs No 2.17 [1.38; 3.43] 0.0006
SBR grade 3 vs. 1-2 1.59 [1.00; 2.52] 0.0484
LDH (U/L) > 500 vs. ≤ 500 2.01 [1.27; 3.16] 0.0026
Lymphocyte count > 700 vs. ≤ 700 0.58 [0.37; 0.89] 0.0138
Total radiation dose (Gy) > 30 vs. ≤ 30 1.54 [0.49; 4.91] 0.463
  1. Abbreviations: KPS: Karnofsky performance status; HR: hormonal receptor; SBR = Scarff-Bloom-Richardson grade; HR = hormone receptor; RTOG = Radiation
  2. Therapy Oncology Group; RPA = recursive partitioning analysis;